UBS ASSET MANAGEMENT AMERICAS LLC - REATA PHARMACEUTICALS INC ownership

REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 94 filers reported holding REATA PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 0.53 and the average weighting 0.4%.

Quarter-by-quarter ownership
UBS ASSET MANAGEMENT AMERICAS LLC ownership history of REATA PHARMACEUTICALS INC
ValueSharesWeighting
Q2 2023$2,349,0090.0%25,8360.0%0.00%0.0%
Q1 2023$2,349,009
+159.7%
25,836
+8.5%
0.00%
Q4 2022$904,466
-99.8%
23,808
+6.9%
0.00%
Q3 2022$559,595,000
-43.2%
22,268
-31.3%
0.00%
-100.0%
Q2 2022$985,456,000
+4.9%
32,427
+13.0%
0.00%
Q1 2022$939,721,000
+36.8%
28,685
+10.1%
0.00%
Q4 2021$686,727,000
-78.1%
26,042
-16.3%
0.00%
-100.0%
Q3 2021$3,129,475,000
-30.8%
31,105
-2.7%
0.00%
-50.0%
Q2 2021$4,522,451,000
+19.3%
31,954
-16.0%
0.00%0.0%
Q1 2021$3,791,391,000
-20.1%
38,028
-1.0%
0.00%0.0%
Q4 2020$4,747,009,000
+48.5%
38,400
+17.1%
0.00%0.0%
Q3 2020$3,195,669,000
-35.9%
32,803
+2.6%
0.00%
-33.3%
Q2 2020$4,987,021,000
+47.1%
31,964
+36.1%
0.00%
+50.0%
Q1 2020$3,390,113,000
-24.6%
23,487
+6.8%
0.00%
-33.3%
Q4 2019$4,494,393,000
+185.2%
21,985
+12.0%
0.00%
+200.0%
Q3 2019$1,575,692,000
+10.9%
19,625
+30.3%
0.00%0.0%
Q2 2019$1,421,383,000
+60.3%
15,065
+45.2%
0.00%0.0%
Q1 2019$886,580,000
+80.8%
10,373
+18.7%
0.00%
Q4 2018$490,370,000
-31.4%
8,7410.0%0.00%
-100.0%
Q3 2018$714,664,000
-80.1%
8,741
-95.0%
0.00%
-66.7%
Q1 2018$3,591,220,000
-31.1%
175,096
-4.8%
0.00%
-25.0%
Q4 2017$5,210,796,000
-10.3%
183,997
-1.5%
0.00%
-20.0%
Q3 2017$5,809,169,000186,7900.01%
Other shareholders
REATA PHARMACEUTICALS INC shareholders Q2 2018
NameSharesValueWeighting ↓
CPMG Inc 3,063,567$298,453,00049.63%
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE 150,000$14,613,00019.62%
Corriente Advisors, LLC 300,000$29,226,00014.82%
Prosight Management, LP 114,554$11,160,0005.31%
MADDEN SECURITIES Corp 43,927$4,279,0003.18%
LBJ Family Wealth Advisors, Ltd. 30,368$2,958,0002.24%
Biondo Investment Advisors, LLC 99,652$9,708,0002.10%
Cormorant Asset Management, LP 450,000$43,839,0001.69%
Duquesne Family Office 543,901$52,987,0001.54%
AWH Capital, L.P. 9,500$925,0001.30%
View complete list of REATA PHARMACEUTICALS INC shareholders